Advances in wearable drug delivery, this conference will review the current trends in the market and highlight the latest technology in this fast growing area.
2-3 Oct 2018
GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 24 Aug
The first “wearable” drug delivery device was developed in the early 1960s, a backpack which delivered insulin to the wearer. Smaller,
more conveniently wearable, syringe-drivers were developed over the following decades for delivery of insulin. These type of devices are now universally known as insulin pumps and the latest versions are stuck directly onto the skin and controlled wirelessly. Ambulatory syringe drivers and bladder pumps are also used for chemotherapy and analgesia.
From the 1980s onwards, wearable passive transdermal patches were developed for dosing a range of drugs such as hormones, analgesics, anti-hypertensives and nicotine to aid smoking cessation. Recently there has been emphasis on development of wearable pumps to deliver larger volumes of biologic drugs, which would be inconvenient to deliver by self-injection.
Why you should attend:
This conference will be beneficial to all those who are interested in learning about, developing or sourcing wearable drug delivery devices. This includes pharmaceutical, medical device and drug delivery companies both large and small. The conference will be of particular interest to R&D, technical, medical, clinical, operating and marketing functions at all levels of
management within these organisations.
Chairman’s welcome and introduction
Emerging trends for novel drug delivery systems
Understanding the market for wearable large volume injectors
Assessing injection site pain
Challenges with high volume and high viscous drug formulations
Demand for large volume injectors
Advances in patch pump technology
Patch pumps and large volume injectors for volumes from 1 to 20 ml
Panel discussion: The challenges associated with large volume injectors
Review of day one
Enterprise connected health and wearable drug delivery
Advances in the fill and finish process for biotech products
Drug delivery solutions for advanced biologics
Challenges of medication delivery in acute and chronic care settings – Implications for delivery device design
Planned changes to the 11608 series of ISO standards and their implications for wearable injectors
Low power wireless for drug delivery applications
Panel discussion: Large volume injections: the opportunity for connected devices
Dr. Andreas Rothmund is Qualified Person at Vetter Pharma-Fertigung in Ravensburg, Germany, an independent contract manufacturer specialised in the aseptic production of pre-filled application systems. He started his industrial career in 1985 as a lab manager. After two years he took over production responsibility for a German company specialised in eye drops and eye ointments, a position he held for nearly eight years. He joined Vetter in 1994, where he has held several positions, including Head of Production for one of Vetter’s aseptic production units. He holds a degree in organic chemistry from the University of Constance, Germany.
Dr. Vincent J. Sullivan is Director, MPS Catheter Applied R&D, for BD Technologies and previously was Senior Scientist and Chemistry/Pharmaceutics Group Leader for BD Technologies, the Corporate Technology and Innovation Center for Becton, Dickinson & Company. He is responsible for research and development on novel drug delivery systems as well as stabilization of vaccines and other biologics. His research at BD has focused on development of systems for respiratory and skin based delivery of drugs and vaccines. He received his PhD in Chemistry from Carnegie Mellon University in 1990, and has over 18 years experience in drug delivery and materials research. Dr. Sullivan holds numerous patents on delivery technologies and has published widely in the fields of medical devices, pharmaceutical formulation, and materials technology. He joined BD in 1999, and was previously employed by Ticona LLC, where he was a Medical Market Segment Leader.
Gregory Berman is an Independent Consultant and Director of Cantab Innovations Ltd. Previously he was Head of the Medical Group at Kinneir Dufort, an award-winning research, innovation, design and product development company, with over 30 years’ experience helping companies discover, create, develop and realise tangible new products, brands and experiences. He helps clients in the life-science, medical and healthcare sectors to develop products in complex situations, optimise life-science R&D and exploit technology strategically. For example he:
Led the design and development of SmartJect™; an autoinjector which automatically retracts the needle and was launched by J&J in 2010 with an important next-generation drug.
Worked with Chrono Therapeutics, helping to develop their SmartStop™ based device, the world’s first programmable, wearable transdermal smoking cessation therapy.
Participated in a detailed design review of an autoinjector being developed by a leading pharmaceutical company for a new drug.
Undertook the Voice of Customer study for a leading biopharmaceutical company, as the starting point for developing high volume parenteral delivery devices for lifesaving immunotherapies.
Undertook a technology survey for a company interested in needle-free, transdermal, micro-needle, electroporation and iontophoresis drug delivery devices.
Ian has been Vice President Business Development, Delivery Systems with Ypsomed AG since 1995. He has had a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Following the successful development and launch of a range of new pen and autoinjector custom products, Ypsomed Delivery Systems’ continues to focus on the development of next generation pen, autoinjector and bolus injector technologies.
Assaf is the Head of Systems Integration at SteadyMed Theraputics Inc. and is responsible for SteadyMed’s PatchPump technology development. He has six years of experience in pumps technology development and holds B.S.E and M.E degrees from the Technion – Israel Institute of Technology.
Uri heads up the drug delivery sector within CDP, leading a variety of design projects including an award-winning needle safety device, an emergency auto-injector, a pen injector packaging design for delivery devices and inhalation products. These projects included compiling design history files and led to successful submissions to both the FDA and the EMA. Uri has worked in industries including aerospace and defence, medical devices, automotive and inkjet. He has extensive knowledge of design for manufacturing and process design, and was involved in setting up several production lines around the world in the automotive inkjet and medical devices sectors.
Steve is head of mechanical engineering for Team Consulting; an award-winning, specialist medical device design consultancy based in Cambridge. Before joining Team nine years ago, Steve worked as a freelance designer for multinational companies including five years working for Glaxo Smith Kline. Most of Steve’s technical work is focussed on drug delivery devices and through this experience he has worked as a member of ISO TC-84 developing the 11608 series of standards over the past five years. A graduate of Loughborough University, Steve also lectures undergraduates on the medical device development process.
Paul Senn has been VP Business Development of Sensile Medical AG since January 2017. Prior to Sensile Paul held several management positions with increasing responsibilities in large and mid sized pharmaceutical and medical device companies in Business Development, Marketing and Development of New Chemical Entities and the design of medical devices. Paul was involved in several major licensing deals as lead negotiator or commercial expert.
Paul holds a Master in Chemistry and a PhD in Physical Chemistry of the University of Basel and received a management education at the IMD in Lausanne.
Robert is responsible for market development of West’s self-injection portfolio in Europe and Asia-Pacific. In this role, he is working closely with customers to understand their delivery device needs and to develop these opportunities together with West’s device/container R&D and commercial organization. Robert has fifteen years’ experience in medical device design and development, high volume manufacturing and global product launches. In his most recent role in market development he was responsible for West’s proprietary COP container European portfolio made from Daikyo Crystal Zenith®, working hand in hand with our strategic partner Daikyo Seiko in Japan. He has studied management and leadership in both European School of Management and Technology, Berlin and INSEAD, The Business School for the World, France.
Neil is the Head of Connected Health and Director of Front-End Innovation for Medicom Innovation Partner, a Phillips-Medisize Company, based in Cambridge UK. Neil consults for BioPharma clients, innovating and executing strategies to enhance stakeholder engagement through connected devices and service design. He has over 22 years’ commercial experience covering medical devices, telemetry, digital imaging, clinical decision support, secure mobile working, patient engagement and health analytics for businesses including Philips Healthcare, Microsoft, Elsevier Health Sciences, Hospira, Map of Medicine and ZOLL. Prior to Neil’s commercial career he trained at Leicester University Hospitals in Operating Department Practice and was Faculty for numerous Advanced Life Support programs having qualified in the UK and United States.
Clare Beddoes is Senior Medical Innovation and Research Consultant with Cambridge Design Partnership. she has been involved in a wide range of medical technology projects across a diverse
subject area. Clare has experience in market strategy, needs analysis, and commercial and technical due diligence and has worked with numerous medical technology companies from start-ups to multinationals.
She has a particular interest in understanding technology innovations within medical technology from the “technology pull” perspective, investigating the unmet needs of key stakeholders within care pathways and helping companies translate those into technology strategy and market approach.
Claire Steed has enjoyed over 25 years in the semiconductor industry and has worked across many disciplines giving her a rounded and insightful view of the market.
Claire obtained her degree in Electronic & Electrical engineering from University of Strathclyde Glasgow and got her first experience of the industry while working summers at Motorola as a sponsored student. After graduating she joined Hitachi Semiconductor (subsequently Renesas) holding field and application engineering roles for low end microcontrollers.
Prior to joining Nordic Semiconductor to lead their UK sales activities, Claire held senior roles in the wireless team at Atmel (subsequently Microchip). Claire has two teenage children and enjoys reading and running when she gets the opportunity.
Chris Muenzer is a Senior Device Technology Manager at Novartis in Basel, Switzerland. He has almost 20 years of development experience with a focus on drug delivery devices and has filed several patents in the field. At Novartis, Mr. Muenzer leads a team supporting injectable delivery systems for Novartis’ diverse portfolio of drugs. In addition to his work at Novartis, he is active on the ISO working group for injection devices. Mr. Muenzer holds a BSME from Carnegie Mellon University in Pittsburgh, Pennsylvania in the US.
Victoria Morgan is Director of Segment Marketing, Global Biogogics, West Pharmaceutical Services, Ireland.
This course qualifies for the following CPD programmes: